➤ Topline Phase 3 pivotal study for BRIMOCHOL for treatment of presbyopia ➤ Positive Phase 2b/3 results for oral treatment of thyroid eye disease ➤ Clinical plan for first-in-human trial for investigational dry AMD therapy ➤ Update on registrational program therapy targeting various retinal diseases ➤ Collaboration to develop RNAi program targeting geographic atrophy ➤ ASCRS news and events
This quality improvement study assesses patient adherence to temperature guidelines for home storage of anti–vascular endothelial growth factor (anti-VEGF) agents in France.
The promise of interoperability for image sharing, and why you should insist that your vendors comply with DICOM standards.
In 2023, two complement inhibitors (CIs) were approved by the FDA for the treatment of geographic atrophy (GA), an advanced form of age-related macular de…
The funding will support activities like formal pharmacology and toxicology testing.
Conexiant Vision: Delivering trusted clinical content, deep audience engagement, and educational resources for eye care professionals. Discover more through our magazines, newsletters, and events.
This secondary analysis of the 3-year results of the 24-Month Myopia Outcome Study of Atropine in Children (MOSAIC) randomized clinical trial investigates the efficacy and…
The new funding will allow the company to complete its ongoing Phase 2 trial of proprietary nanomedicine, migaldendranib, in patients with wet AMD and DME
Ophthalmology Times – ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic community.
OCU400 demonstrated meaningful improvement of 2-line gain (10 letters on ETDRS chart) in low-luminance visual acuity (LLVA) in treated eyes when compared to untreated fellow…
